Response of human liver tissue to innate immune stimuli

Xia Wu[1, *], Jessica B. Roberto[1], Allison Knupp[1], Alexander L. Greninger[1,3], Camtu D. Truong[1],

Nicole Hollingshead[1], Heidi L. Kenerson[2], Marianne Tuefferd[4], Antony Chen[4], Helen Horton[4],

Keith R. Jerome[1,3], Stephen J. Polyak[1], Raymond S. Yeung[2] and Ian N. Crispe[1]

[1]Department of Laboratory Medicine and Pathology, and [2]Department of Surgery, University of

Washington, Seattle, WA, USA 98195

[3]Fred Hutchinson Cancer Research Institute, Seattle, Washington, USA.

[4]Infectious Diseases and Vaccines, Janssen Research and Development, B-2340 Beerse,

Belgium.

*To whom correspondence should be addressed:

Xia Wu, Ph.D.

Department of Medicine, University of Washington,

750 Republican St., E630, Seattle, WA 98109

E-mail: xiawu2@uw.edu Tel: 1-206-221-3343

Keywords: liver slice culture, innate immunity, Hepatitis C virus, direct-acting antiviral

treatment, inflammation, fibrosis

24   **Short Title**: innate immune response with PCLS

26   **Number of figures and tables**

27   6 figures, 1 table

Conflict of Interest statement

The authors declare no relevant conflicts of interest.

Financial support

This work was supported by NIH NIAID R56 grant AI143683; US Department of Defense grant

CA150370; Janssen Research and Development; the Seattle Foundation; and the University of

Washington.

Acknowledgements

We thank Pathology Research Services Laboratory, and Histology and Imaging Core (HIC) at

UW for their help in data and image acquisition.

Authors' contributions

X.W., J.B.R., A.C., H.H., R.S.Y. and I.N.C. designed research; X.W., J.B.R., A.K., A.L.G.,

N.H., H.L.K, M.T. and A.C. performed research; K.R.J., S.J.P. and R.S.Y. contributed

reagents/analytic tools; X.W., A.L.G., C.D.T. and I.N.C. analyzed data; X.W., S.J.P. and I.N.C.

wrote the manuscript; all authors reviewed the manuscript and provided suggestions.

70 **Abbreviations**

71 Abbreviations are provided for some terms not commonly known; some are also explained in the

72 manuscript. Authors will conform with journal standards if paper is accepted scientifically.

74	PCLS	precision-cut liver slice
75	TLR	toll-like receptor
76	NPC	non-parenchymal cell
77	KC	Kupffer cells
78	LSEC	Liver sinusoidal endothelial cells
79	HSC	hepatic stellate cells
80	HCV	hepatitis C virus
81	DAA	direct-acting antiviral
82	ISGs	interferon-stimulated genes
83	HCC	hepatocellular carcinoma
84	ICC	intrahepatic cholangiocarcinoma
85	SVR	sustained virologic response

Abstract

Precision-cut human liver slice cultures (PCLS) has become an important alternative

immunological platform in preclinical testing. To further evaluate the capacity of PCLS, we

investigated the innate immune response to TLR3 agonist (poly-I:C) and TLR4 agonist (LPS)

with the normal and pathological liver tissue. Pathological liver tissue was obtained from

patients with active chronic HCV infection, and patients with former chronic HCV infection

cured by recent Direct-Acting Antiviral (DAA) drug therapy. We found that hepatic innate

immunity was not suppressed but enhanced in the HCV-infected tissue, compared with the

healthy controls. Furthermore, despite recent HCV elimination, DAA-cured liver tissue

manifested ongoing abnormalities in liver immunity. Sustained abnormal immune gene

expression in DAA-cured samples were identified from direct *ex vivo* measurements and with

TLR3 and TLR4 stimulation assays. Those genes that were up-regulated in chronic HCV-

infected liver tissue were enriched in expression in the liver non-parenchymal cell compartment.

These results demonstrated the utility of PCLS in studying the liver pathology and innate

immunity.

Introduction

We recently reported the development of human liver slice technology (PCLS) as an

immunological platform[1,2]. Compared with other liver research methods, the PCLS method has

the advantage that hepatocytes and the major subsets of non-parenchymal cells (KC, LSEC and

HSC) are cultured together in their normal anatomical relationships, enabling the analysis of

liver cell function in the context of intercellular interaction. Furthermore, the patterns of liver

disease that are present in fresh tissue could be maintained over time in the slice cultures[1]. For

example, steatotic liver slices retains fat droplets, and cholestatic liver slices were manifested

with yellow-green pigment in hepatocytes.   However, it remained unclear whether PCLS has the

capacity to reveal the dynamic alternations in innate immune response that may occur in

pathological liver tissue compared with healthy controls. As a proof of principle, we compared

the dynamic response with PCLS with liver tissue collected from three groups of patients which

included non-infected subjects, chronic HCV-infected patients, and patients whose HCV was

cured by DAA treatment.

HCV-infected liver tissue is of particular interest, because HCV infection is one of the most

common liver diseases in the USA and globally. Approximately 71 million individuals are

infected with HCV worldwide [3]. The acute phase of infection is often subclinical, but 55–85%

of infected individuals develop a chronic infection leading to progressive liver pathology [4]. The

World Health Organization (WHO) estimated that approximately 399,000 people died from

HCV- related diseases in 2016, mostly from cirrhosis and hepatocellular carcinoma (HCC).

The recent introduction of highly effective direct-acting antiviral (DAA) drugs has presented a

unique opportunity to investigate the resolution of pathological liver to normality after HCV

elimination. The extent to which such drugs revert the liver to normal is not fully resolved, with

some studies suggesting that HCV clearance with DAA therapy leaves residual abnormalities in

innate immunity in peripheral monocytes and NK cells [5,6], adaptive immunity in peripheral

CD4+ and CD8+ T cells [7-10], in γδ-T cells [11], in mucosal associated invariant T cells [12], and in

the persisting risk to hepatocellular cancer [13-16]. Other studies also found abnormal serum lipids

[17], persistent epigenetic modifications [18,19], and sustained hepatic inflammation [20] in liver

biopsies after DAA treatment. To our knowledge, no studies have evaluated hepatic immunity of

untreated versus DAA-treated HCV infection in the context of intact liver tissue.

Materials and Methods

Liver samples, preparation and culturing

Fresh non-tumor liver tissues were obtained from patients undergoing liver resection at the

University of Washington Medical Center (Seattle, WA, USA). All patients in this study

prospectively consented to donate liver tissue for research under the Institutional Review Board

protocol #00001852. Tissue from DAA-treated patients were collected from those who

achieved sustained virologic response (SVR), with HCV viral load being non-detected after the

completion of DAA therapy. Clinical details of these patients are provided in **Table S1**.

Liver slicing and culturing were as previously described [1]. Briefly, liver cores of 6 mm diameter

were excised from the resected liver tissue using a biopsy punch (Integra Miltex, York, PA,

USA), stored in BELZER-UW solution (Bridge to Life Ltd., Columbia, SC, USA), and

transferred to the research laboratories typically within 1 h of tissue excision. Slices 250 μm

thick were prepared using a vibrating microtome, Leica VT1200 S (Nussloch, Germany), using

Dulbecco's Modified Eagles Medium (DMEM) as the cutting medium. Liver slices were

cultured individually on 0.4 μm millicell organotypic inserts in 24 well plates (Millipore

Corporation, Billerica, MA, USA). The culturing medium comprised $1 \times$ advanced-DMEM

medium, 5% Fetal Bovine Serum (FBS), $1 \times$ GlutaMAX, $0.5 \times$ Penicillin-Streptomycin, $1 \times$

Insulin-Transferrin-Selenium supplement and 15 mM HEPES (pH 7.2 - 7.5) (all from Gibco,

Grand Island, NY, USA). The liver cultures were maintained on a rocking platform at 17 rpm in

a humidified incubator at 5% CO_2 and atmospheric concentration of O_2 at 37°C. The medium

was renewed every two to three days.

Histology of liver slices

Liver slices were fixed with the 10% neutral-buffered formalin at room temperature for 24 h. The

fixed liver slices were embedded in paraffin and were sliced into 4 μm-thick sections.

Trichrome stain, picrosirius red stain, and hematoxylin and eosin (H&E) stain were analyzed

with the standard protocol in the Pathology Research Services Laboratory at Department of

Laboratory Medicine and Pathology at UW. The fibrosis score of liver slices was analyzed by a

pathologist blinded from the patient clinical diseases. The Scheuer/Batts-Ludwig method was

used for fibrosis scoring, with 0: No fibrosis, 1: portal fibrosis, 2: peri-portal fibrosis, 3: bridging

fibrosis, and 4: cirrhosis.   The whole-slide images were recorded with Nanozoomer Whole Slide

Scanner (Hamamatsu City, Shizuoka Pref., Japan) and visualized with NDP.view2 software

(Hamamatsu).

Liver perfusion and isolation of liver cells

Human liver cell isolation procedures were adapted from several sources [21,22]. Cell isolation was

performed on wedges of resected tissue rather than cores.   Perfusion buffer contained $1 \times$ Hank's

Balanced Salt Solution (HBSS, without Ca++, Mg++, or phenol red, from Gibco), 10 mM

HEPES (pH 7.2-7.5) and 0.5 mM EDTA (pH 8.0).   Collagenase buffer contained $1 \times$ HBSS

(Gibco), 5 mM $MgCl_2$, 5 mM $CaCl_2$, 5 mM HEPES (pH 7.2-7.5), 0.5% w/v Collagenase IV

(Sigma-Aldrich, St. Louis, MO, USA), 0.25% w/v Protease (Sigma), 0.125% w/v Hyaluronidase

(Sigma), 0.05% w/v DNase I (Sigma).   Fresh aliquots of enzymes were added to the buffer on

the day of the perfusion experiment.   Forty mL of Perfusion buffer and 20 mL of Collagenase

buffer were used for each 10 g of liver tissue.   Buffers were pre-warmed to 37°C prior to the

perfusion step.

Liver tissue wedges were sequentially perfused with Washing buffer ($1 \times$ HBSS and 10 mM

HEPES, pH 7.2-7.5), Perfusion buffer, Washing buffer, and the recirculating Collagenase buffer

at a flow rate of 12 mL/min (Gilson's MINIPULS 3, Middleton, WI, USA).   The perfused liver

tissue samples were gently mashed with a sterile syringe plunger through a sterile mesh strainer

in ice-cold DMEM medium.   Cell extracts were filtered through a 100 μm sterile strainer and

centrifuged at $50 \times g$ at 4°C for 3 min to enrich for hepatocytes in the pellets and non-

parenchymal cells in the supernatant. The supernatants were transferred to a new tube and kept

on ice. The pellets were washed three times with ice-cold DMEM medium, and were pelleted

each time at $50 \times g$ at 4°C for 3 min.   To further improve the purity of the isolated hepatocytes,

cell pellets were resuspended with 5 mL of ice-cold PBS, overlaid with 10 mL of 25% Percoll

gradient solution. The mixture was centrifuged at $1400 \times g$ (no brake) at 4°C for 20 min. The

pellet contained the purified live hepatocytes.   The viability of the isolated hepatocytes was

determined with the trypan blue exclusion assay (Thermo Fisher Scientific, Waltham, MA,

USA).   If the viability was greater than 50%, the isolated hepatocytes were stored for RNA

extraction.

For the non-parenchymal cells (NPC), the 50 x g centrifuge supernatants were further

centrifuged at $500 \times g$ at 4°C for 7 min.   The pellets were resuspended in 5 mL of ice-cold PBS,

and overlaid on top with 50% and 25% Percoll gradients (10 mL layers each), and were

centrifuged at $1400 \times g$ (no brake) at 4°C for 20 min. Cell layers were collected into 20 mL PBS

each, and centrifuged again at $500 \times g$ at 4°C for 7 min. A fraction of the pellets were saved for

RNA extraction, which were the total NPC. The rest of the pellets were resuspended with the

ice-cold Flow buffer containing $1 \times$ PBS, 2% FBS, and 1 mM EDTA.   Experimental Overview

is illustrated in Fig. S1.

Flow cytometry and cell sorting

The isolated non-parenchymal cells were stained with an antibody mixture that included

eBioscience (San Diego, CA, USA): anti-CD45 (Cat. No. 15-0459-42); BioLegend (San Diego,

CA, USA): anti-CD3 (Cat. No. 317330), anti-CD11b (Cat. No. 553310), anti-CD14 (Cat. No.

301834), anti-CD31 (Cat. No. 303120), anti-CD32 (Cat. No. 303206), anti-CD68 (Cat. No.

333814), and anti-CD271 (Cat. No. 345110). In addition, cells were also stained with

LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Cat. No. L10120, Life Technologies,

Carlsbad, CA, USA). The incubation mixture was kept at 4°C for 30 min in the dark on a

rocking platform. The mixture was centrifuged with $500 \times g$ at 4°C for 7 min. Cells were

washed once with Flow buffer.

The antibody-labeled cells were sorted with a BD Aria III (BD Biosciences, San Jose, CA,

USA). Analysis of cell populations was performed using FlowJo software, version 9.8.5

(FlowJo, LLC, Ashland, OR, USA). Kupffer cells were selected as the CD45+, CD3−, CD14+,

CD68+, CD32+ populations [23,24]. LSECs were selected as CD45−, CD31+, CD11b− [25]. HSCs

were selected as CD45−, CD271+, autofluorescence positive with the emission wavelength at

460 nm, SSC-H > 150 units [26,27] (**Fig. S1**). Cells were pelleted at $500 \times g$ at 4°C for 7 min, and

were stored in -80°C before RNA extraction.

RNA isolation and qRT-PCR analysis

The RNA of liver slices or the purified liver cells was isolated with TRIzol and the Direct-zol

RNA MiniPrep Kit (Zymo Research, Irvine, CA, USA). The RNA concentration was measured

with nanoDrop (Thermo Fisher Scientific). The cDNA was synthesized with the QuantiTect

Reverse Transcription Kit (Qiagen, Hilden, Germany).

A pre-amplification was performed before the multiplex qRT-PCR assays to improve the

detection sensitivity [28,29], which included PCR reactions of cDNA as templates, and the 0.2 fold-

diluted primer mixture of TaqMan assays of interest (Thermo Fisher Scientific) and the BIO-X-

ACT Short Mix reagents (Bioline USA Inc., Taunton, MA, USA).   The pre-amplified samples

were diluted five-fold with RNase- and DNase-free H_2O. Samples were analyzed with a 48×48

dynamic array and a BioMark HD microfluidics system (Fluidigm, San Francisco, CA, USA).

The Fluidigm Real-Time PCR Analysis software was used to calculate Ct thresholds, using the

settings of quality threshold 0.65, baseline correction linear, Ct threshold method auto detection.

Gene abundance of individual liver slices was normalized to the arithmetic mean of Ct values of

ACTB, HPRT, and GAPDH. Typically, three liver slices were analyzed for each subject for

each time point. The arithmetic mean delta Ct of three liver slices was used to in the figures and

for statistical analysis. The hierarchical clustering was analyzed with Cluster 3.0 [30]. Heat map

was visualized with Java Treeview (version 1.1.6r4) [31].

HCV RNA measurement

HCV RNA was measured with a Food and Drug Administration-approved Abbott Real-Time

HCV assay (Abbott Molecular, Des Plaines, IL, USA) as previously described [20,32]. Fifty ng of

total RNA for each sample was input in the assay, and HCV IU/ng total RNA was calculated

from the calibration curve of positive controls. The reliable detection limit for HCV with this

assay was 1.2 IU/ 50 ng liver total RNA.

Validation of liver cell types with cell-type-specific genes

Liver cell-type-specific genes for hepatocytes, Kupffer cells (KC), liver sinusoidal endothelial

cells (LSEC) and hepatic stellate cells (HSC) were obtained from previous microarray analysis

of liver FACS purified cells [1] and recent publications of liver single cell RNAseq [33,34].

Enrichment of the FACS purified liver cell types were confirmed by the selective expression of

cell-type-specific genes.

Ex vivo **stimulation of liver slices with poly-I:C and LPS**

Liver slices were cultured *ex vivo* for 7 days. Final concentrations of 15 μg/mL polyinosinic–

polycytidylic acid (poly-I:C) (Sigma, Cat. No. P1530), 1.5 μg/mL lipopolysaccharide endotoxin

(LPS) (Sigma, Cat. No. L2630) or $1 \times$ PBS (control, matched by volume) were added to the

growth medium. During the stimulation, liver slices were maintained on transwell inserts placed

on a rocking platform at 37°C. Three liver slices were harvested at each time point, including 0

h (time zero control), 2 h, 4 h, 8 h, 12 h or 24 h. The concentrations of poly-I:C and LPS

treatments were based on our previous studies with isolated liver leukocytes [35] and liver slices [1].

Statistical significance test

The non-parametric Mann Whitney test, Kruskal-Wallis test with Dunn's post test with multiple

test comparison correction, and Wilcoxon matched-pairs signed rank test were performed using

Prism (version 9.1.0) (GraphPad Software Inc., CA, USA). Multiple comparison correction was

not applied in the gene expression analysis, because a specific set of genes were targeted for

analysis unlike the standard procedure in a data-driven functional genomics study. In this

circumstance, correction for type I error is not advised, because the correction could lead to

inflation of type II error (i.e. false negatives) [36]. The issue of type II errors also arises because

of the limited number of tissue samples available to us. For these reasons, we treated each gene

we selected as an individual measurement.

Results

As a first step, we verified the robust response of liver slices during poly-I:C and LPS exposure

(**Fig. 1, S2**). The added 2 h time point confirmed that *IFN-α*, *IFN-β*, *IFN-γ* and *IFN-λ* was

stimulated prior to the elevation of interferon-stimulated genes *IFIT1/2*, *MX1*, *CXCL10* and

RSAD2 by poly-I:C. The induction of these antiviral genes was greater with poly-I:C compared

with LPS induction (**Fig. 1, S2**). In contrast, *IL1B* and *IL6* were more robustly stimulated by

LPS. The response of *IL1B* and *IL6* extended to 24 h post stimulation; in comparison, TNF

peaked at 2 h, and gradually declined at 4, 8, 12, 24 h post-stimulation time points (**Fig. S2**).

The temporal and gene specificity in poly-I:C and LPS response provided the basis for further

dynamic testing of HCV-infected and DAA-cured liver tissue.

Detection and quantitation of HCV RNA with liver slices

Liver tissue from eight chronic HCV-infected patients were studied. All eight patients were

diagnosed with primary liver cancer, either hepatocellular carcinoma (HCC) or intrahepatic

cholangiocarcinoma (ICC). Four HCV genotypes were identified including HCV G1a, G1b, G2,

G6. Likewise, liver tissue from ten DAA-cured patients were studied. The DAA-cured patients

completed 8-24 weeks of DAA therapy. All subjects achieve sustained virologic response (SVR)

with HCV RNA below the limit of detection after completion of DAA treatment. However, these

DAA-cured patients were diagnosed with primary liver cancer (HCC or ICC) post DAA therapy.

The time from completion of DAA treatment to liver resection surgery (i.e. the time liver tissue

was collected) ranged from less than 1 month to 20 months, with a median of 9 month post-DAA

therapy completion (**Table S1**).

To assure the identity of HCV infection, HCV copies and genotype were analyzed by UW

virology clinic using the FDA-approved HCV assays. Liver slices originated from the chronic

HCV patients were all confirmed with detectable HCV RNA, ranged from 1.2 to 9760.1 with the

median value 3325.4 IU/50 ng total RNA. In comparison, none of the non-infected or DAA-

treated subjects were positive for HCV RNA *ex vivo* based on the limit of detection of 1.2 IU/50

ng total RNA (**Fig. 2A**). Moreover, chronic HCV-infected liver slices continued to be HCV

positive after 7 days of *ex vivo* culture (**Fig. 2B),** with a range of 1.8-14365.8, and median 405

IU/50 ng total RNA. The viral load on day 7 did not significantly differ from day 0 (Wilcoxon

matched-pairs signed rank test, two-tailed, P=0.4688). Previous study showed that HCV can

replicate in human liver slices culture for more than 10 days [37].

Fibrosis in chronic HCV-infected and DAA-cured liver tissue

Because chronic HCV infection induced liver cirrhosis, we examined the liver tissue for fibrosis

using picrosirius red and Masson's trichrome staining (**Fig. 2C**). Previous indirect

measurements with transient elastography and noninvasive fibrosis indices reported regression of

liver fibrosis after DAA treatment [38,39]. Nevertheless, direct analysis of the liver tissue revealed

that six out of eight DAA-cured patients met the definition of cirrhosis (i.e. fibrosis score of 4,

Scheuer/Batts-Ludwig method) in livers despite the absence of HCV RNA, even after 20 months

after DAA therapy (**Fig. 2C, Fig.3**). Likewise, the untreated chronic HCV livers were fibrotic as

expected [40]. None of the non-infected subjects had advanced liver fibrosis. Since the duration

between the liver tissue collection and the time point of SVR ranged from less than 1 month to

20 months, it remains plausible that the fibrosis will be slowly resolved over a greater time span.

As a result of the fibrotic status in HCV-infected and DAA-cured liver tissue, and that HCV-free

fibrotic liver tissue was not available in this study, an important caveat is that the abnormal

immune gene expression in both the HCV-infected and the DAA-cured liver slices could result

either directly from HCV infection, or as a consequence of the fibrosis. .

Immune gene abnormality in chronic HCV-infected and DAA-cured *ex vivo*

We used multiplex qRT-PCR to examine 140 genes functioning in immune activation and

suppression, and tissue repair.   Forty immune genes differed in expression in chronic HCV-

infected livers versus non-infected patients (Mann Whitney test, two-tailed, $P < 0.05$) (**Fig. 4A**).

This included antiviral interferon (IFN)-stimulated genes (ISGs) including *IFIT1/2/3, ISG15,*

RSAD2, MX1, CXCL9, CXCL10, consistent with previous reports [41-44]. In addition, immune

activation genes including MHC genes *HLA-A, HLA-DRA*, *CIITA*, *CD80, CD86*, tumor necrosis

factor (TNF) superfamily genes *OX40, 4-1BB, TNFSF9, TNFRSF18* and inflammation genes

including *CASP1, IL-12A, IL-12B, TNF, IL-18*, and *NFKB* were also significantly up-regulated

in HCV-infected livers (**Fig. 4A**).

DAA treatment restored the antiviral genes to baseline, as reported previously [45], but some

immune genes were remained elevated after cure of HCV infection. These included immune

activation genes (*HLA-A, CIITA, 4-1BB, CCL5, CCR2*), inflammatory genes (*CASP1, IL-12A*),

and immune suppression genes (*CTLA4, TIGIT, IDO1, ARG1*). (**Figs. 4A**)

The phosphoinositol-3-kinase (PI3K) pathway-linked genes are susceptible to modification by

HCV infection [18] and liver fibrosis [46,47]. We found that *SPHK1, BTG2, SOX9, SNAP25*, and

GPRC5B were significantly up-regulated in chronic HCV infected livers. Furthermore, *SPHK1,*

BTG2, and *SOX9* remained significantly up-regulated after HCV clearance with DAA treatment

(**Fig. 4A**).

Immune gene subsets mapped to hepatic non-parenchymal immune cells

To identify the cellular origin of the dysregulated immune gene subsets, we investigated gene

expression with liver specific cells purified from FACS [1]. Six liver wedge samples of non-

infected liver tissue were large enough in size and anatomically ideal for perfusion through the

vasculature, which allowed them to be dissociated and analyzed for gene expression. We could

not do this with samples of DAA-cured patients due to limitations in the amount of liver tissue

obtained. Liver cell types were confirmed with respective cell expression markers[1,33,48],

including *FCN1, NLRP3, ITGA4* for KC, *EMCN, VWF, CD34* for *LSEC, FGFR2, PDGFRB,*

COL1A1, LRAT for HSC, and *FBP1, RBP4, ALB* for hepatocytes (**Fig. S3**).

Many immune genes that were up-regulated in HCV-infected or DAA-cured fibrotic liver tissue

were significantly enriched in the Non-Parenchymal Cell (NPC) compartment (**Table 1, Figs.**

4B). For a smaller subset of immune genes, we were able to map them to specific immune cells

with greatest expression, for example *CIITA* mapped to Kupffer cells (KC)*, HLA-A* and *CX3CL1*

mapped to liver sinusoidal endothelial cells (LSEC), and *IL-12B* mapped to Hepatic Stellate

Cells (HSC) (**Fig. 4B, Fig. S4**). Even though NPC may not include the cell types targeted by

HCV infection, previous studies demonstrate that NPC can be activated through paracrine

signaling from the neighboring HCV-infected hepatocytes [43,49,50].

Innate immune responses were altered in HCV infected and DAA-cured liver tissue

We stimulated liver slices with poly-I:C and LPS for varying times using the method established

in our previous study [1]. We chose day 7 as the time to add stimuli because the immune genes

activated by tissue slicing had broadly stabilized after 4 days of *ex vivo* culture [1]. The immune

genes were recorded at the day 7 baseline prior to the treatment. A number of the immune genes

remained at elevated baseline in HCV-infected or DAA-cured samples compared with non-

infected control (**Fig. 4AB**). The PBS mock stimulation did not significantly induce IFNs and

ISGs in liver slices [1]. Notably, expression of TLR3, TLR4 themselves and NF-κB transcription

factor were not significantly different at day 7 among chronic HCV-infected, DAA-treated and

non-infected liver slices (**Fig. S5A**).   We used the ΔCt method with internal normalization to

ACTB, GAPDH and *HPRT* to evaluate the overall abundance level post stimulation (**Fig. S6**).

We also used the $\Delta\Delta$Ct method against the day 7 T_0 to assess the enhanced net increase of genes

during TLR3/TLR4 response (**Fig. 5**). We confirmed that TLR3 and TLR4 are primarily

expressed in the NPC compartment (**Fig. S5B**).

First, robust induction of IFNs and ISGs by both TLR3 and TLR4 agonists was observed in liver

slices from all three groups of liver specimens (*i.e.*, non-infected, HCV-infected, and DAA-

cured). The sequential signaling cascade induced by TLR3 and TLR4 pathways described in

Fig.1 and **Fig. S1** for non-infected liver tissue, were also pronounced in the HCV-infected and

DAA-cured liver tissue. For example, *IFNB1* and *IFNL3* (IL28B) peaked at 2-4 h, prior to the

maximum abundance of ISGs (*IFIT 1/2/3, RSAD2* and *MX1*) which occurred at 4-8 (**Figs. 5 and**

S6).

Second, some immune genes were not suppressed but induced more strongly by TLR3 agonist in

liver slices of chronic HCV-infected liver at least at one time point (Mann-Whitney test, two

tailed, P < 0.05). These included antiviral genes *MX1, RSAD2, IFNG*, chemokine genes *CCL3,*

CX3CL1, CXCL9, inflammatory genes *TNF, CASP1* and *IL-10* (**Fig. S7**). Other common

activation markers for TLR3 signaling, including *IFNB1, IL28B, IFIT 1/2/3, ISG15, CXCL10,*

IL-1B and *CCL-5*, were also responsive in chronic HCV-infected slices with elevation of greater

than 10-fold, as strong as changes in the non-infected liver slices. Thus, TLR3 sensing and

signaling did not appear to be impaired in chronic HCV-infected liver slices. Furthermore, *TNF,*

IL-10 and *RSAD2* remained abnormally induced at 12 h and 24 h in chronic HCV liver slices,

indicating persistent inflammation.

TLR4 sensing and signaling were similarly robust in chronic HCV-infected livers. *IFIT1, IFIT3,*

RSAD2, MX1, CCL3, CASP1 and *IL-10* were again identified along with *IL-8, IL-1B, IL-1A* and

IL12B at greater abundance post LPS stimulation in chronic HCV-infected liver slices on at least

one time point (Mann-Whitney test, two tailed, P < 0.05) (**Fig 6A**).

Third, most of the hyper-induction of the genes in HCV-infected tissue (9/11 genes in TLR3

response, 12/18 genes in TLR4 response) was not reversed in the tissue from formerly HCV+,

but now successfully treated donors. *IFIT2, IFNB1, CCL5*, *ISG15* and *IL12B* were more

strongly induced by LPS in DAA-cured tissue, previously not identified with HCV-infected

tissue (**Fig. 6B**).

In terms of the ΔΔCt net increase, *TNF, CTGF, IL-10, CX3CL1* were more strongly induced by

both polyI:C and LPS in both HCV-infected and DAA-cured liver tissue. *IL-1B* and *IL-8* in

HCV-infected, and *IFIT2* in DAA-cured liver tissue were more responsive to LPS (**Fig. 6B**).

Importantly, a subset of these genes *TNF, CX3CR1* in KC, *CTGF* in LSEC, *CCL7, ISG15* for

HSC, and *IL-8, IL-1B, RSAD2, CXCL9, CCL3* for NPCs were only revealed through the TLR3

and TLR4 stimulation assays, but not with the *ex vivo* day 0 measurements. These results

highlighted the unique value to measure dynamic changes with liver tissue to reveal immune

signaling defects (**Fig. 6B**).

Discussion

In this study, we pioneered the PCLS technology to study innate immune response with the

normal and pathological liver tissue. We showed that immune abnormalities persist after the

elimination of HCV by anti-viral therapy, and the persisting inflammatory and immune

signatures mapped to hepatic non-parenchymal cells. Innate immunity was not suppressed but

enhanced in HCV-infected tissue, and these abnormalities were not corrected after effective

DAA treatment.

In human hepatocyte cultures [51,52] HCV infection triggered cleavage of MAVS and TRIF host

proteins by HCV NS3/4A protease, disrupting TLR3-antiviral signaling. Reduction of protein

levels of MAVS and TRIF was also observed previously in chronic HCV-infected livers [53,54].

Nevertheless, we observed a robust response to TLR3 signaling in the HCV-infected liver, which

supports the idea that ISG induction is weak in HCV infected cells, but strong in HCV infected

liver due to paracrine activation of NPC. The data on the direct effect of HCV on the TLR3

response in liver tissue are novel and distinct from previous work focused on the IFN-induced

gene expression in chronically HCV-infected liver by pegylated IFN therapy [55,56], since such

direct activation of IFN signaling bypasses MAVS and TRIF.

A previous study reported that HBV does not interfere with innate immune response based on

chronic HBV-infected liver biopsy tissues [57]. However, in chronic HCV-infected tissue, we

found innate immunity to TLR3 and TLR4 was not suppressed but enhanced. The different

outcome may reflect the differences in immune evasion mechanisms between DNA and RNA

viruses. Furthermore, the tissue status and treatment method were not identical between two

studies. In chronic HCV-infected tissue, advanced fibrosis was observed, and this study also used

the day 7 as treatment time zero when immune activation by tissue slicing was broadly

stabilized.

From the days of IFN-based therapy, we know that HCV-induced liver disease can regress when

the virus is eradicated from the liver [58]. However, halting or reversing liver disease upon IFN

cure of HCV has not been universal; some patients with advanced disease still go on to develop

HCC [59-61]. DAA drugs are now able to cure the majority of HCV infections, even in subjects

with advanced liver disease. Nevertheless, clearance of HCV with DAA treatment may only

partially restore immune cell function. In this study, we have identified immune genes that were

restored to normal by DAA treatment, and more importantly immune genes that were not

restored *ex vivo* (*i.e.*, at day 0 time point), including a subset of immune activation genes,

inflammation genes, immune suppression, and PI3K pathway genes.

The era during which some, but not all HCV patients were treated with DAA was brief and has

passed. Within this narrow time window, we worked with tissue from patients who were treated

for surgical resection of a liver lesion. Accordingly, there are inherent limitations to this study.

First, due to the small sample size, we did not further classify patient subgroups based on HCV

genotypes. Likewise, other subject characteristics including gender, age, genetic polymorphisms

(such as *IL28B*), and liver fibrosis status, all of which may affect immunity and responses to

HCV infection [14,62,63] were not used as factors to subdivide patient groups in the downstream

analysis. Surprisingly, we observed significant effects that cut across these hidden variables,

with consistent identification of aberrant immune gene at baseline day 0 and day 7, as well as

those with altered TLR3 and TLR4 responses. Second, we cannot determine how far the

sustained abnormality is due to the host response to hepatic fibrosis or HCC rather than HCV-

mediated. The DAA-cured subjects we studied were based only on those who developed HCC

or ICC post DAA therapy, since these were the patients who were subject to liver resection.

Thus, our DAA-cured samples only covered a unique sub-group of DAA-cured patients.   Future

study may extend the conclusion through analysis of a more diverse group of clinical situations,

including chronic HCV patients and DAAs-SVR cases with or without fibrosis or HCC, as well

as non-HCV related liver tissues with fibrosis or HCC.   Liver tissue with longer time span post

DAA therapy (>20 months) will also help clarify the resolution of liver cirrhosis by DAA

therapy.

We made use of the PCLS approach opportunistically to obtain data from the group of untreated

HCV-infected subjects, a group that has now disappeared from the surgical patient pool. While

many of the scientific conclusions need to be tentative because of the heterogeneity of both

subjects and controls, this study demonstrates the power of PCLS to document functional

responses of intact human liver tissue. With appropriate selection of tissue sources, it will add

much to the study of human liver immunopathology.

References

1   Wu, X. *et al.* Precision-cut human liver slice cultures as an immunological platform.
528   *Journal of immunological methods* **455**, 71-79, doi:10.1016/j.jim.2018.01.012
529   (2018).

2   Kenerson, H. L., Sullivan, K. M., Labadie, K. P., Pillarisetty, V. G. & Yeung, R. S. Protocol
for tissue slice cultures from human solid tumors to study therapeutic response.
STAR Protoc **2**, 100574, doi:10.1016/j.xpro.2021.100574 (2021).

3   Polaris Observatory, H. C. V. C. Global prevalence and genotype distribution of
hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol*
2, 161-176, doi:10.1016/S2468-1253(16)30181-9 (2017).

4   Ringelhan, M., McKeating, J. A. & Protzer, U. Viral hepatitis and liver cancer. *Philos*
Trans R Soc Lond B Biol Sci **372**, doi:10.1098/rstb.2016.0274 (2017).

5   Zhang, Q. *et al.* HCV core protein inhibits polarization and activity of both M1 and
M2 macrophages through the TLR2 signaling pathway. *Sci Rep* **6**, 36160,
doi:10.1038/srep36160 (2016).

6   Spaan, M. *et al.* Immunological Analysis During Interferon-Free Therapy for Chronic
Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell
Compartment. *J Infect Dis* **213**, 216-223, doi:10.1093/infdis/jiv391 (2016).

7   Aregay, A. *et al.* Elimination of Hepatitis C Virus has limited impact on the functional
and mitochondrial impairment of HCV-specific CD8+ T cell responses. *Journal of*
hepatology, doi:10.1016/j.jhep.2019.06.025 (2019).

8   Najafi Fard, S. *et al.* Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-
cells responses, but does not alter T-cells activation among HCV mono-infected, and
HCV/HIV-1 co-infected patients. *Clin Res Hepatol Gastroenterol* **42**, 319-329,
doi:10.1016/j.clinre.2017.11.006 (2018).

9   Telatin, V. *et al.* In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell
Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful
Direct-Acting Antiviral Treatment. *Front Cell Infect Microbiol* **9**, 190,
doi:10.3389/fcimb.2019.00190 (2019).

10   Vranjkovic, A. *et al.* Direct-Acting Antiviral Treatment of HCV Infection Does Not
Resolve the Dysfunction of Circulating CD8(+) T-Cells in Advanced Liver Disease.
Front Immunol **10**, 1926, doi:10.3389/fimmu.2019.01926 (2019).

11   Ghosh, A. *et al.* Persistent gamma delta T-cell dysfunction in chronic HCV infection
despite direct-acting antiviral therapy induced cure. *Journal of viral hepatitis* **26**,
1105-1116, doi:10.1111/jvh.13121 (2019).

12   Hengst, J. *et al.* Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus
infection despite successful interferon-free therapy. *Eur J Immunol* **46**, 2204-2210,
doi:10.1002/eji.201646447 (2016).

13   Reig, M. *et al.* Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. *Journal of hepatology* **65**, 719-726,
doi:10.1016/j.jhep.2016.04.008 (2016).

14   Conti, F. *et al.* Early occurrence and recurrence of hepatocellular carcinoma in HCV-
related cirrhosis treated with direct-acting antivirals. *Journal of hepatology* **65**, 727-
733, doi:10.1016/j.jhep.2016.06.015 (2016).

15   Kuftinec, G. *et al.* De novo hepatocellular carcinoma occurrence in hepatitis C
cirrhotics treated with direct-acting antiviral agents. *Hepat Oncol* **5**, HEP06,
doi:10.2217/hep-2018-0003 (2018).

16   Dong Ji, e. a. Increase in Incidence of Hepatocellular Carcinoma in Chronic Hepatitis
C Chinese After Sustained Virologic Response with Direct Acting Antiviral Agents as

Compared to Pegylated Interferon Plus Ribavirin Therapy: A Prospective Open-
Label Study. *Preprint with THE LANCET* **preprint** (2019).

17   Gitto, S. *et al.* Worsening of Serum Lipid Profile after Direct Acting Antiviral
Treatment. *Ann Hepatol* **17**, 64-75, doi:10.5604/01.3001.0010.7536 (2018).

18   Hamdane, N. *et al.* HCV-Induced Epigenetic Changes Associated With Liver Cancer
Risk Persist After Sustained Virologic Response. *Gastroenterology* **156**, 2313-2329
e2317, doi:10.1053/j.gastro.2019.02.038 (2019).

19   Perez, S. *et al.* Hepatitis C virus leaves an epigenetic signature post cure of infection
by direct-acting antivirals. *PLoS Genet* **15**, e1008181,
doi:10.1371/journal.pgen.1008181 (2019).

20   Whitcomb, E. *et al.* Biopsy Specimens From Allograft Liver Contain Histologic
Features of Hepatitis C Virus Infection After Virus Eradication. *Clin Gastroenterol*
Hepatol **15**, 1279-1285, doi:10.1016/j.cgh.2017.04.041 (2017).

21   Bhogal, R. H. *et al.* Isolation of primary human hepatocytes from normal and
diseased liver tissue: a one hundred liver experience. *PloS one* **6**, e18222,
doi:10.1371/journal.pone.0018222 (2011).

22   Mohar, I., Brempelis, K. J., Murray, S. A., Ebrahimkhani, M. R. & Crispe, I. N. Isolation
of Non-parenchymal Cells from the Mouse Liver. *Methods in molecular biology* **1325**,
3-17, doi:10.1007/978-1-4939-2815-6_1 (2015).

23   Alabraba, E. B. *et al.* A new approach to isolation and culture of human Kupffer cells.
Journal of immunological methods **326**, 139-144, doi:10.1016/j.jim.2007.06.014
(2007).

24   Ikarashi, M. *et al.* Distinct development and functions of resident and recruited liver
Kupffer cells/macrophages. *Journal of leukocyte biology* **94**, 1325-1336,
doi:10.1189/jlb.0313144 (2013).

25   Elvevold, K., Smedsrod, B. & Martinez, I. The liver sinusoidal endothelial cell: a cell
type of controversial and confusing identity. *American journal of physiology.*
Gastrointestinal and liver physiology **294**, G391-400, doi:10.1152/ajpgi.00167.2007
(2008).

26   Buhring, H. J. *et al.* Novel markers for the prospective isolation of human MSC.
Annals of the New York Academy of Sciences **1106**, 262-271,
doi:10.1196/annals.1392.000 (2007).

27   D'Ambrosio, D. N. *et al.* Distinct populations of hepatic stellate cells in the mouse
liver have different capacities for retinoid and lipid storage. *PloS one* **6**, e24993,
doi:10.1371/journal.pone.0024993 (2011).

28   Brempelis, K. J., Yuen, S. Y., Schwarz, N., Mohar, I. & Crispe, I. N. Central role of the
TIR-domain-containing adaptor-inducing interferon-beta (TRIF) adaptor protein in
murine sterile liver injury. *Hepatology* **65**, 1336-1351, doi:10.1002/hep.29078
(2017).

29   Jang, J. S. *et al.* Quantitative miRNA expression analysis using fluidigm microfluidics
dynamic arrays. *BMC genomics* **12**, 144, doi:10.1186/1471-2164-12-144 (2011).

30   Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display
of genome-wide expression patterns. *Proceedings of the National Academy of*
Sciences of the United States of America **95**, 14863-14868 (1998).

31   Saldanha, A. J. Java Treeview--extensible visualization of microarray data.
Bioinformatics **20**, 3246-3248, doi:10.1093/bioinformatics/bth349 (2004).

32 Elmasry, S. *et al.* Detection of Occult Hepatitis C Virus Infection in Patients Who
Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for
Recurrent Infection After Liver Transplantation. *Gastroenterology* **152**, 550-553
e558, doi:10.1053/j.gastro.2016.11.002 (2017).
33 MacParland, S. A. *et al.* Single cell RNA sequencing of human liver reveals distinct
intrahepatic macrophage populations. *Nat Commun* **9**, 4383, doi:10.1038/s41467-
018-06318-7 (2018).
34 Aizarani, N. *et al.* A human liver cell atlas reveals heterogeneity and epithelial
progenitors. *Nature* **572**, 199-204, doi:10.1038/s41586-019-1373-2 (2019).
35 Tu, Z. *et al.* TLR-dependent cross talk between human Kupffer cells and NK cells. *The*
Journal of experimental medicine **205**, 233-244, doi:10.1084/jem.20072195 (2008).
36 Armstrong, R. A. When to use the Bonferroni correction. *Ophthalmic Physiol Opt* **34**,
502-508, doi:10.1111/opo.12131 (2014).
37 Lagaye, S. *et al.* Efficient replication of primary or culture hepatitis C virus isolates in
human liver slices: A relevant ex vivo model of liver infection. *Hepatology* **56**, 861-
872, doi:10.1002/hep.25738 (2012).
38 Dolmazashvili, E. *et al.* Regression of liver fibrosis over a 24-week period after
completing direct-acting antiviral therapy in patients with chronic hepatitis C
receiving care within the national hepatitis C elimination program in Georgia:
results of hepatology clinic HEPA experience. *European journal of gastroenterology*
& hepatology **29**, 1223-1230, doi:10.1097/MEG.0000000000000964 (2017).
39 Hsu, W. F. *et al.* Rapid decline of noninvasive fibrosis index values in patients with
hepatitis C receiving treatment with direct-acting antiviral agents. *BMC*
gastroenterology **19**, 63, doi:10.1186/s12876-019-0973-5 (2019).
40 Mittal, S. *et al.* Hepatocellular Carcinoma in the Absence of Cirrhosis in United States
Veterans is Associated With Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol*
Hepatol **14**, 124-131 e121, doi:10.1016/j.cgh.2015.07.019 (2016).
41 Negash, A. A. *et al.* IL-1beta production through the NLRP3 inflammasome by
hepatic macrophages links hepatitis C virus infection with liver inflammation and
disease. *PLoS Pathog* **9**, e1003330, doi:10.1371/journal.ppat.1003330 (2013).
42 Lau, D. T. *et al.* Interferon regulatory factor-3 activation, hepatic interferon-
stimulated gene expression, and immune cell infiltration in hepatitis C virus
patients. *Hepatology* **47**, 799-809, doi:10.1002/hep.22076 (2008).
43 Brownell, J. *et al.* Independent, parallel pathways to CXCL10 induction in HCV-
infected hepatocytes. *Journal of hepatology* **59**, 701-708,
doi:10.1016/j.jhep.2013.06.001 (2013).
44 Brownell, J. *et al.* Direct, interferon-independent activation of the CXCL10 promoter
by NF-kappaB and interferon regulatory factor 3 during hepatitis C virus infection. *J*
Virol **88**, 1582-1590, doi:10.1128/JVI.02007-13 (2014).
45 Meissner, E. G. *et al.* Endogenous intrahepatic IFNs and association with IFN-free
HCV treatment outcome. *The Journal of clinical investigation* **124**, 3352-3363,
doi:10.1172/JCI75938 (2014).
46 Wang, L. *et al.* Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via
VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells.
EBioMedicine **43**, 525-536, doi:10.1016/j.ebiom.2019.04.050 (2019).

47   Cai, C. X. *et al.* Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate
Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis. *Digestive diseases and*
sciences **62**, 968-978, doi:10.1007/s10620-017-4470-9 (2017).
48   Wu, X. *et al.* Human Liver Macrophage Subsets Defined by CD32. *Front Immunol* **11**,
2108, doi:10.3389/fimmu.2020.02108 (2020).
49   Dreux, M. *et al.* Short-range exosomal transfer of viral RNA from infected cells to
plasmacytoid dendritic cells triggers innate immunity. *Cell Host Microbe* **12**, 558-
570, doi:10.1016/j.chom.2012.08.010 (2012).
50   Wieland, S. *et al.* Simultaneous detection of hepatitis C virus and interferon
stimulated gene expression in infected human liver. *Hepatology* **59**, 2121-2130,
doi:10.1002/hep.26770 (2014).
51   Loo, Y. M. *et al.* Viral and therapeutic control of IFN-beta promoter stimulator 1
during hepatitis C virus infection. *Proc Natl Acad Sci U S A* **103**, 6001-6006,
doi:10.1073/pnas.0601523103 (2006).
52   Li, K. *et al.* Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage
of the Toll-like receptor 3 adaptor protein TRIF. *Proc Natl Acad Sci U S A* **102**, 2992-
2997, doi:10.1073/pnas.0408824102 (2005).
53   Bellecave, P. *et al.* Cleavage of mitochondrial antiviral signaling protein in the liver
of patients with chronic hepatitis C correlates with a reduced activation of the
endogenous interferon system. *Hepatology* **51**, 1127-1136, doi:10.1002/hep.23426
(2010).
54   Kar, P., Kumar, D., Gumma, P. K., Chowdhury, S. J. & Karra, V. K. Down regulation of
TRIF, TLR3, and MAVS in HCV infected liver correlates with the outcome of
infection. *J Med Virol* **89**, 2165-2172, doi:10.1002/jmv.24849 (2017).
55   Sarasin-Filipowicz, M. *et al.* Interferon signaling and treatment outcome in chronic
hepatitis C. *Proc Natl Acad Sci U S A* **105**, 7034-7039, doi:10.1073/pnas.0707882105
(2008).
56   McGilvray, I. *et al.* Hepatic cell-type specific gene expression better predicts HCV
treatment outcome than IL28B genotype. *Gastroenterology* **142**, 1122-1131 e1121,
doi:10.1053/j.gastro.2012.01.028 (2012).
57   Suslov, A., Boldanova, T., Wang, X., Wieland, S. & Heim, M. H. Hepatitis B Virus Does
Not Interfere With Innate Immune Responses in the Human Liver. *Gastroenterology*
154, 1778-1790, doi:10.1053/j.gastro.2018.01.034 (2018).
58   D'Ambrosio, R. & Colombo, M. Should surveillance for liver cancer be modified in
hepatitis C patients after treatment-related cirrhosis regression? *Liver international*
: official journal of the International Association for the Study of the Liver **36**, 783-
790, doi:10.1111/liv.13106 (2016).
59   Makiyama, A. *et al.* Characteristics of patients with chronic hepatitis C who develop
hepatocellular carcinoma after a sustained response to interferon therapy. *Cancer*
101, 1616-1622, doi:10.1002/cncr.20537 (2004).
60   van der Meer, A. J. *et al.* Risk of cirrhosis-related complications in patients with
advanced fibrosis following hepatitis C virus eradication. *Journal of hepatology* **66**,
485-493, doi:10.1016/j.jhep.2016.10.017 (2017).
61   van der Meer, A. J. *et al.* Association between sustained virological response and all-
cause mortality among patients with chronic hepatitis C and advanced hepatic
fibrosis. *JAMA* **308**, 2584-2593, doi:10.1001/jama.2012.144878 (2012).

62   Schott, E. *et al.* Gender-dependent association of CTLA4 polymorphisms with
resolution of hepatitis C virus infection. *Journal of hepatology* **46**, 372-380,
doi:10.1016/j.jhep.2006.09.011 (2007).
63   Yan, Z. & Wang, Y. Viral and host factors associated with outcomes of hepatitis C
virus infection (Review). *Mol Med Rep* **15**, 2909-2924, doi:10.3892/mmr.2017.6351
(2017).

Figure legends

See figures

Table

Table 1 Immune gene changes *ex vivo* (Day 0)

	Fold change			Statistical significance[2]			Cell-type-specific information[3]
	[1]HCV/ Con	DAA/ Con	DAA/ HCV	HCV/ Con	DAA/ Con	DAA/ HCV	
Antiviral genes							
Cured by DAA at D0 baseline[4]							
CXCL10	54.39	2.93	0.05	0.0003	0.4598	0.0004	NPC, KC
RSAD2	7.68	1.05	0.14	0.0007	0.7197	0.0007	NPC
IFIT1	7.16	1.51	0.21	0.0007	0.211	0.002	NPC
IFIT3	7.02	1.61	0.23	0.0002	0.0653	0.0004	NPC
CXCL9	6.80	1.45	0.21	0.0016	0.7197	0.0017	NPC, HSC
IFIT2	5.39	1.82	0.34	0.0007	0.0535	0.033	NPC, HSC
ISG15	6.16	1.04	0.17	0.0115	0.8421	0.0012	likely NPC, HSC
MX1	7.05	1.01	0.14	0.0004	0.9682	0.0002	likely NPC
Immune activation genes							
NOT cured by DAA at D0 baseline[5]							
HLA-A	3.84	1.61	0.42	0.0002	0.022	0.0012	NPC, LSEC
CCL5	3.30	1.92	0.58	0.0033	0.022	0.0878	NPC
CCR2	9.93	4.45	0.45	0.0007	0.0104	0.02	likely NPC
4-1BB (CD137, TNFRSF9)	6.35	3.17	0.50	0.0007	0.0279	0.0702	likely NPC
CIITA	5.03	4.64	0.92	0.0007	0.0003	0.6691	likely KC
Cured by DAA at D0 baseline							
HLA-DRA	2.53	1.43	0.56	0.0052	0.2775	0.1088	NPC
CD80	3.54	1.91	0.54	0.0012	0.1823	0.0553	NPC
CD86	2.32	1.25	0.54	0.0418	0.447	0.1613	NPC
OX40 (TNFRSF4)	3.93	2.46	0.63	0.0033	0.0789	0.3638	LSEC
TNFRSF18	5.62	2.97	0.53	0.0006	0.0745	0.351	HSC, LSEC
TNFSF9	2.97	2.08	0.70	0.036	0.2224	0.2721	likely KC
CXCL1	2.73	1.01	0.37	0.1447	0.9048	0.003	HSC
IFNG	2.69	0.83	0.31	0.1738	>0.9999	0.0431	NPC
Inflammation genes							
NOT cured by DAA at D0 baseline							
CASP1	3.13	2.71	0.87	0.0007	0.0435	0.0136	NPC
IL-12A	3.71	1.91	0.51	0.0037	0.0434	0.0185	LSEC

Cured by DAA at D0 baseline							
IL-12B	2.86	1.29	0.45	0.0262	0.7577	0.1738	HSC
TNF	2.77	1.06	0.38	0.0115	0.7802	0.0046	NPC, KC, HSC
IL-18	2.40	0.90	0.37	0.0164	0.6607	0.025	NPC, HSC
NFKB	1.46	1.01	0.69	0.0283	>0.9999	0.0317	N/A
Immune Suppression genes							
NOT cured by DAA at D0 baseline							
CTLA4	6.52	2.70	0.41	0.0003	0.0172	0.033	likely NPC
TIGIT	4.77	3.20	0.67	0.0003	0.0172	0.033	likely NPC
IDO1	4.35	2.52	0.58	0.0052	0.0435	0.1613	NPC
ARG1	0.45	0.39	0.89	0.0229	0.0056	0.6806	Hep, uncommon in KC, LSEC
Cured by DAA at D0 baseline							
B7-H4	4.49	3.70	0.83	0.0059	0.0541	0.7104	HSC
VISTA (VSIR)	2.10	1.40	0.67	0.0021	0.1333	0.3638	KC, LSEC, HSC
CD47	1.43	1.24	0.87	0.0418	0.3562	0.3148	NPC, KC, LSEC, HSC
PDCD1	5.16	2.30	0.44	0.0205	0.0592	0.1416	not cell-type-specific
LAG3	1.88	1.19	0.64	0.0164	>0.9999	0.0712	not cell-type-specific
TIM3	2.18	0.99	0.46	0.0079	0.8633	0.0164	NPC
FOXP3	2.94	0.70	0.24	0.1416	0.8633	0.0079	not cell-type-specific
PI3K pathway genes							
NOT cured by DAA at D0 baseline							
SPHK1	3.50	2.13	0.61	0.0052	0.04	0.2523	HSC
BTG2	2.19	2.10	0.96	0.0907	0.0188	0.8371	N/A
SOX9	2.62	2.30	0.88	0.0549	0.04	>0.9999	Not cell-type-specific
SNAP25	3.03	1.88	0.62	0.0164	0.0503	0.351	N/A
GPRC5B	2.30	1.91	0.83	0.0311	0.1615	0.351	N/A
Tissue repair genes							
Cured by DAA at D0 baseline							
TIMP1	1.98	1.29	0.65	0.0311	0.447	0.2698	LSEC
MMP9	2.04	1.13	0.56	0.0164	0.7802	0.1331	Not cell-type-specific
PDGFB	1.62	0.93	0.58	0.2523	0.8633	0.0164	LSEC
TGFB1	2.18	1.27	0.58	0.0712	0.447	0.0431	KC, LSEC, HSC

Liver tissue was perfused, and total livers, hepatocytes (Hep) and NPC populations (NPC) were obtained with differential centrifugation. Kupffer cells (KC), liver sinusoidal endothelial cells (LSEC), and hepatic stellate cells (HSC) enriched populations were obtained with FACS from NPC (Fig. 1B). RNA was extracted from each cell type, followed by qRT-PCR gene expression analysis using the fluidigm platform.

[1]The comparisons were HCV/ Con, chronic HCV-infected versus non-infected controls; DAA/ Con, DAA-cured versus non-infected controls; DAA/HCV, DAA-cured versus chronic HCV-infected.

[2]Statistical significance was based on non-parametric two-tailed Mann-Whitney test.
[3]Cell-type-specific information was based on analysis of the non-HCV-infected samples. N/A means cell-type-specific gene information not analyzed. This was due to the limit of sample availability and the assay through-put with fluidigm assays.

[4]Cured by DAA at D0 baseline categorized the gene subsets that were normalized to the same level as non-infected controls.

[5]Not cured by DAA at D0 baseline categorized gene subsets that were not normalized to the correct levels as the non-infected controls.

Figure 1. Innate immune response of human liver slices to polyI:C or LPS treatment. Non-HCV-infected specimens are shown. IFN-β, IFN-γ and IFN-λ expression peaked at 2-4 h, whereas interferon-stimulated gene expression for IFIT1, MX1 and CXCL10 peak round 4-12 h. Each marker represents a patient time-point summary which consist of 2-3 biological replicates of liver slices. Relative abundance at the log2 scale is shown, with the median, 25% and 75% quantile values indicated with violin plots.

Figure 2. HCV and fibrosis analysis with human liver slices. (A) All eight chronic HCV samples (blue color) were confirmed with positive HCV RNA detection. None of the DAA cured subjects (red color) or the non-infected controls (black color) was positive for HCV RNA. n.d., meaning non-detected. The limit of reliable detection (LoD) was 1.2 IU/ 50 ng liver total RNA. (B) HCV RNA remained robustly detected in the day 7 liver slices cultured from chronically HCV-infected patients. The viral load between day 0 and day 7 liver slices was not statistically significant (P=0.4688, Wilcoxon matched-pairs signed rank test). (C) Fibrosis analysis of the day 0 *ex vivo* liver specimens with trichrome staining and picrosirius red staining indicated that in DAA-treated, and now HCV-negative patients in this study there was persistent fibrosis, similar to untreated HCV and different from tissue without a history of HCV infection. The scoring system was based on the Scheuer/Batts-Ludwig method. Data included 10 non-infected patients, 4 chronic HCV patients, and 8 DAA-treated patients, with the minimum and maximum data points for each subgroup being shown. Statistical significance was based on Mann-Whitney test. **, P < 0.01. ††, P < 0.01

Figure 3. Examples of trichrome stain, picrosirius red stain, and H&E stain analysis of human liver slices.
Arrow indicates the nodule formation in the cirrhosis livers. The Scheuer/Batts-Ludwig method was used for fibrosis scoring, with 0: No fibrosis, 1: portal fibrosis, 2: peri-portal fibrosis, 3: bridging fibrosis, and 4: cirrhosis. The DAA-4 liver tissue was collected 12 months after the completion of 24-week DAA therapy,   DAA-9 liver tissue was collected 20 months after the completion of 12-week DAA therapy.

A

Day 0 — HCV vs Con. / DAA vs Con.
Day 7 — HCV vs Con. / DAA vs Con.

Elevated genes in HCV and DAA at Day 7

Elevated genes in HCV at Day 7

Elevated genes in DAA at Day 7

Log2 (Fold-change)

B Abnormal genes at Day 7 baseline

Figure 4. Immune gene changes at the day 7 baseline in chronic HCV-infected and DAA-cured livers. (A) Hierarchical clustering of immune genes with statistically significant elevation in HCV or DAA-cured subjects at Day 0 or Day 7 time points. The group-level fold changes are shown, which were calculated with the mean Ct value of each gene within each patient group. Decreased fold changes are colored in green, and increased fold changes are colored in red. (B) The up-regulated genes in HCV and DAA-cured at day 7 time points. Genes were mapped to liver cell types according to the cell type analysis with day 0 non-infected livers. Genes are grouped by expression patterns in cell compartments and in specimens type. The overlapped genes up-regulated at both day 0 and day 7 time points are bolded and underscored.

Figure 5. Delta-delta Ct analysis showing up-regulated genes post- poly-I:C or LPS stimulation in chronic HCV-infected and DAA-cured liver slices. The relative gene abundance was normalized to to the arithmetic mean of Ct values of ACTB, GAPDH and HPRT1. The relative abundance was further normalized to the day 7 time zero measurements. Statistical significance was based on two-tailed Mann-Whitney test. *, statistical significantly different between non-infected versus chronic HCV liver slices. †, statistical significantly different between non-infected versus DAA-cured liver slices. ‡, statistical significantly different between chronic HCV versus DAA-cured liver slices. Levels of statistical significance *, P <0.05 **, P<0.01, ***, P<0.001. The mean and standard deviation within each group are plotted.

Figure 6

Figure 6. Altered TLR3 and TLR4 response in chronic HCV-infected liver slices not restored in DAA-cured liver slices. (A) Hierarchical clustering of immune responsive genes with 2-fold or greater induction during LPS stimulation. The statistical significance P value with ΔCt method is shown. Gene abundance of individual liver slices was normalized to the arithmetic mean of Ct values of ACTB, GAPDH and HPRT. Two-tailed Mann-Whitney test was used. Greater significance P value is colored with darker red. (B) Immune genes up-regulated in polyI:C or LPS treatment were mapped to live cell compartment according to the day 0 information. Genes identified with ΔΔCt method, i.e. with an enhanced net increase during TLR3/TLR4 response is highlighted with a black bordering. Genes elevated in HCV- or DAA- samples or both are colored accordingly. Elevated genes were grouped by whether they were differentially expressed in TLR3 or TLR4 treatment not at the baseline level, and whether polyI:C or LPS treatment revealed differential responses. Antiviral genes RSAD2, CXCL9, MX1, IFIT3 were corrected at baseline in DAA-cured samples, but manifested abnormal up-regulation during polyI:C and LPS treatment.